REGN News Alert Regeneron Pharmaceuticals (REGN) 400.12 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Regeneron Pharmaceuticals (REGN) 400.12 $REGN

Why I Expect The Biotech Sell-Off To Continue Into 2015
Sammy Pollack - at Seeking Alpha - Wed Dec 24, 7:08AM CST

BIIB: 340.89 (+5.13), ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), IBB: 299.80 (+5.12), AMGN: 160.67 (+3.15), REGN: 400.12 (+6.07), CELG: 109.60 (+3.48)

Regeneron's Valuation Has Moved Ahead Of Its Growth Potential
Stock Market Sherpa - at Seeking Alpha - Wed Dec 24, 6:27AM CST

REGN: 400.12 (+6.07)

Watch for Regeneron Pharmaceuticals to Potentially Rebound After Falling 4.58% Yesterday
Comtex SmarTrend(R) - Tue Dec 23, 3:44PM CST
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $383.87 to a high of $410.96. Yesterday, the shares fell 4.6%, which took the trading range below the 3-day low of $410.15 on volume of 2.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
REGN: 400.12 (+6.07)

Dow Reaches Record Close as Santa Claus Rally Hits Day 5
at The Street - Tue Dec 23, 3:04PM CST
The Dow Jones Industrial Average breaks through 18,000 on Tuesday as third-quarter GDP shows signs of better-than-expected economic health.
PSX: 72.10 (-0.46), HTZ: 24.38 (-0.09), GMCR: 137.65 (+1.10), OCN: 14.88 (-0.14), XOM: 93.78 (-0.81), NQ: 4.32 (-0.36), XLV: 68.64 (+0.50), AGO: 26.28 (+0.23), ESRX: 85.48 (-0.40), RDN: 16.78 (+0.18), GILD: 91.29 (+1.84), ACHN: 13.06 (+1.22), CHK: 19.84 (-0.45), ABBV: 66.21 (+1.86), CVX: 113.47 (-0.48), SWN: 28.46 (-0.46), WAG: 76.67 (+0.16), REGN: 400.12 (+6.07), XLE: 80.13 (-0.59)

Fresh Milestones For Dow, S&P 500 But Biotechs Hit
at Investor's Business Daily - Tue Dec 23, 1:48PM CST
The Dow Jones industrial average and S&P 500 notched fresh all-time highs Tuesday, but the Nasdaq lagged as biotech stocks sold off hard. The Dow added 0.6%, with about one-third of its components up 1% or more. The S&P 500 rose 0.4% and the Nasdaq...
BIIB: 340.89 (+5.13), VRX: 140.33 (-0.22), CDW: 35.75 (+0.14), CELG: 109.60 (+3.48), NOAH: 20.44 (-1.00), BIDU: 230.98 (-2.18), CALM: 42.45 (-1.73), ABG: 77.12 (+0.43), FLT: 149.17 (-0.93), REGN: 400.12 (+6.07)

Dow, S&P 500 Near Session Highs After GDP Growth Smashes Expectations
at The Street - Tue Dec 23, 1:25PM CST
The Dow Jones Industrial Average breaks through 18,000 on Tuesday as third-quarter GDP shows signs of better-than-expected economic health.
GPRO: 66.41 (+4.87), GMCR: 137.65 (+1.10), OCN: 14.88 (-0.14), NQ: 4.32 (-0.36), XLV: 68.64 (+0.50), AGO: 26.28 (+0.23), ESRX: 85.48 (-0.40), RDN: 16.78 (+0.18), GILD: 91.29 (+1.84), ACHN: 13.06 (+1.22), CHK: 19.84 (-0.45), ABBV: 66.21 (+1.86), SWN: 28.46 (-0.46), WAG: 76.67 (+0.16), REGN: 400.12 (+6.07)

Dow Crosses 18,000 But Medical-Related Groups Fall Hard
at Investor's Business Daily - Tue Dec 23, 12:22PM CST
The Dow Jones industrial average and S&P 500 notched fresh all-time highs Tuesday, cheered by a robust upward revision to Q3 gross domestic product. The Dow was in the driver's seat in early afternoon trading, but the Nasdaq had a hard time keeping...
DD: 74.79 (-0.40), BA: 131.24 (+1.21), EPAM: 48.84 (+0.33), CDW: 35.75 (+0.14), REGN: 400.12 (+6.07), CELG: 109.60 (+3.48)

Dow Industrials Top 18,000 but Biopharma Stocks Drag Nasdaq Lower
at The Street - Tue Dec 23, 10:29AM CST
The Dow Jones Industrial Average breaks through 18,000 on Tuesday as stock markets gain.
AVP: 9.22 (-0.07), GMCR: 137.65 (+1.10), NQ: 4.32 (-0.36), SBUX: 81.27 (-0.16), AGO: 26.28 (+0.23), ESRX: 85.48 (-0.40), RDN: 16.78 (+0.18), GILD: 91.29 (+1.84), ACHN: 13.06 (+1.22), CHK: 19.84 (-0.45), ABBV: 66.21 (+1.86), SWN: 28.46 (-0.46), WAG: 76.67 (+0.16), REGN: 400.12 (+6.07)

Jim Cramer Answers Twitter (TWTR) Questions on Gilead, WhiteWave Foods, and More
at The Street - Mon Dec 22, 12:37PM CST
TheStreet's Jim Cramer answers Twitter (TWTR) questions from the floor of the New York Stock Exchange.
WWAV: 35.98 (+0.72), BIIB: 340.89 (+5.13), ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), VALE: 8.09 (-0.05), KRFT: 63.90 (-0.11), ABBV: 66.21 (+1.86), DF: 18.96 (-0.01), TWTR: 37.61 (+0.04), PANW: 125.99 (+0.77), REGN: 400.12 (+6.07), K: 67.02 (-0.22), CELG: 109.60 (+3.48)

Stocks Struggle To Hold Gains; Alaska Air, Spirit Up
at Investor's Business Daily - Mon Dec 22, 9:34AM CST
Stocks got off to a mixed start, but quickly turned positive in the shortened holiday week, with drugmakers showing particular weakness at Monday's open. The Dow Jones industrial average led, up 0.4%. The Nasdaq backed out of early losses to a 0.2%...
BIIB: 340.89 (+5.13), ESRX: 85.48 (-0.40), SAVE: 75.68 (+1.52), GILD: 91.29 (+1.84), MRK: 57.46 (+0.25), AMGN: 160.67 (+3.15), ABBV: 66.21 (+1.86), ALK: 58.72 (+1.97), REGN: 400.12 (+6.07), CELG: 109.60 (+3.48)

The Market's 10 Best Stocks
Dan Caplinger, The Motley Fool - Motley Fool - Sun Dec 21, 7:02AM CST
Source: Wikimedia Commons. Investors are always searching for the best possible stocks. That's because if you can identify a winning stock before it takes off, it can have a life-changing impact on your finances. In order to find those stocks,...
NFLX: 342.10 (+5.67), NEU: 405.00 (+5.94), MNST: 112.56 (+0.52), OPK: 9.63 (+0.21), GMCR: 137.65 (+1.10), ALXN: 181.96 (+3.09), ILMN: 186.22 (+2.72), AAPL: 112.01 (-0.53), REGN: 400.12 (+6.07), PCLN: 1,149.78 (+2.17)

Seeking Alpha's Biotech Weekly: A Merck Purchase, Spectacular Auspex, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Dec 19, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. What should the Seeking Alpha community be reading and writing about? Please leave...
SPHS: 0.46 (+0.02), ASPX: 49.93 (-0.10), MDVN: 99.23 (+1.23), CYCC: 0.69 (+0.01), OPK: 9.63 (+0.21), NLNK: 39.08 (+1.36), JUNO: 39.99 (+2.71), REGN: 400.12 (+6.07), MYGN: 36.50 (+0.28), PFE: 31.42 (-0.03), IMGN: 5.90 (+0.13), AMGN: 160.67 (+3.15), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), BLRX: 1.68 (-0.01), OREX: 5.98 (+0.01), DVA: 76.06 (+0.07), BLCM: 19.30 (+0.18), CBST: 100.29 (-0.09), GILD: 91.29 (+1.84), GERN: 3.06 (+0.05), MRK: 57.46 (+0.25), NVS: 93.91 (+0.66)

Cramer: ‘Downside’ to Biotech as ImmunoGen Stock Cut in Half
at The Street - Fri Dec 19, 9:46AM CST
TheStreet's Jim Cramer takes a look at Celgene's positive news, as well as the bad news that caused shares of ImmunoGen to be nearly cut in half.
BIIB: 340.89 (+5.13), ISIS: 59.49 (+1.88), GILD: 91.29 (+1.84), IMGN: 5.90 (+0.13), REGN: 400.12 (+6.07), CELG: 109.60 (+3.48)

Regeneron Announces Presentation and Panel Discussion at the 33rd Annual J.P. Morgan Healthcare Conference
PR Newswire - Fri Dec 19, 8:30AM CST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the 33rd Annual J.P. Morgan Healthcare Conference as follows:
JPM: 62.48 (unch), REGN: 400.12 (+6.07)

The Best Healthcare Stocks of 2014: Which Is Our Favorite for 2015?
Todd Campbell, The Motley Fool - Motley Fool - Fri Dec 19, 6:44AM CST
From Medicaid expansion to cancer drugs to minimally invasive treatment for heart disease, Industry Focus looks at the 10 top performers among large-cap healthcare stocks in 2014. There were some surprises on the list this year, with strong showings...
AGN: 210.12 (+0.95), MDVN: 99.23 (+1.23), CNC: 105.96 (+1.03), JNJ: 104.59 (+0.31), VRX: 140.33 (-0.22), ACT: 254.20 (-1.68), EW: 130.75 (+1.17), SNY: 46.35 (+0.50), REGN: 400.12 (+6.07)

Hypercholesterolemia - Pipeline Review, H2 2014
M2 - Fri Dec 19, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/5snkwx/hypercholesterolem) has announced the addition of the "Hypercholesterolemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypercholesterolemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypercholesterolemia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hypercholesterolemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hypercholesterolemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - Johnson & Johnson - Amgen - Eli Lilly and Company - Merck & Co - Pfizer - Santaris Pharma - SoluBest - Alnylam Pharmaceuticals - Regeneron Pharmaceuticals - CrystalGenomics - Catabasis Pharmaceuticals - Planet Biotechnology - Zhejiang Hisun Pharmaceutical - Esperion Therapeutics - Progenra - Serometrix - Hanmi Pharmaceuticals - AtheroNova. - Immune Response BioPharma - Agilvax - Michigan Life Therapeutics - LondonPharma - Dybly For more information visit http://www.researchandmarkets.com/research/5s...lesterolem
JNJ: 104.59 (+0.31), ESPR: 35.97 (-0.08), MRK: 57.46 (+0.25), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), BMY: 59.15 (-0.01), REGN: 400.12 (+6.07)

Cramer's Mad Money - Which Biotech Is The Next Regeneron? (12/18/14)
SA Editor Miriam Metzinger - Seeking Alpha - Fri Dec 19, 4:45AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday December 18. Recipe For a Rally: Rite Aid (NYSE: RAD ), Kraft (NASDAQ: KRFT ), Accenture (NYSE: ACN ), Darden (NYSE: DRI ), Boeing (NYSE: BA ), 3M (NYSE:...
MMM: 166.96 (+0.09), ISIS: 59.49 (+1.88), Q: 59.48 (+0.01), JBL: 21.88 (+0.17), WYNN: 150.90 (-0.79), KRFT: 63.90 (-0.11), MGM: 20.77 (-0.17), BA: 131.24 (+1.21), ACN: 91.32 (-0.10), REGN: 400.12 (+6.07), DRI: 58.42 (-0.09), RAD: 7.26 (-0.09)

Jim Cramer's 'Mad Money' Recap: 10 Reasons We'll Have a Santa Claus Rally
at The Street - Thu Dec 18, 7:10PM CST
Cramer lists 10 ingredients in this seasonally strong market that will lead to a rally.
WFM: 48.67 (-0.40), MMM: 166.96 (+0.09), WMT: 86.43 (-0.23), HSBC: 47.71 (+0.18), M: 64.26 (+0.22), BA: 131.24 (+1.21), CELG: 109.60 (+3.48), SBUX: 81.27 (-0.16), RIG: 18.77 (-0.37), ISIS: 59.49 (+1.88), JPM: 62.48 (unch), Q: 59.48 (+0.01), GILD: 91.29 (+1.84), KBR: 17.00 (-0.13), FLR: 60.30 (-0.26), COST: 143.65 (-0.50), REGN: 400.12 (+6.07)

'Mad Money' Lightning Round: GE Is a Good Stock With Good Yield
at The Street - Thu Dec 18, 5:00AM CST
Cramer is skittish on Sanofi, can't recommend C&J Energy Services and doesn't want you in Annaly Capital.
NLY: 11.21 (-0.05), GE: 25.83 (-0.05), CJES: 13.39 (-0.29), BCRX: 11.83 (+0.76), DDD: 30.54 (-0.64), AGIO: 109.67 (+2.45), ABBV: 66.21 (+1.86), BMY: 59.15 (-0.01), SNY: 46.35 (+0.50), HPQ: 40.54 (+0.18), REGN: 400.12 (+6.07), CELG: 109.60 (+3.48)

Jim Cramer's 'Mad Money' Recap: Why This Market Is All About Velocity
at The Street - Wed Dec 17, 7:16PM CST
A day's rest from the selling in oil will allow investors, analysts and oil companies themselves some time to assess their situations, Cramer says.
MNST: 112.56 (+0.52), BCRX: 11.83 (+0.76), CJES: 13.39 (-0.29), GE: 25.83 (-0.05), CLX: 105.46 (-0.62), DDD: 30.54 (-0.64), KMB: 117.77 (-0.21), RRD: 16.84 (+0.07), BMY: 59.15 (-0.01), KS: 29.97 (+0.03), HPQ: 40.54 (+0.18), CELG: 109.60 (+3.48), HAIN: 117.25 (+0.23), NLY: 11.21 (-0.05), CVS: 97.89 (+0.02), ABBV: 66.21 (+1.86), AGIO: 109.67 (+2.45), SNY: 46.35 (+0.50), REGN: 400.12 (+6.07)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 110

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
CITGO Sign Return Caps Kenmore's Careful Rebuild Work

Updated Category News Views 88

Thirty feet upward and 120 feet eastward is not the sort of move that usually stops a city in its tracks, yet Boston’s CITGO Sign was never merely rooftop hardware. Its public relighting in Kenmore Square marks the final phase of the redevelopment at 660 Beacon Street, and the real accomplishment is less flashy than the lights: a beloved, federally landmarked object...

Continue Reading
Lara Kirchner's Surgical Leadership Earns Recognition

Updated Category News Views 83

Surgical care gets judged in the quiet moments nobody puts on a plaque: a sterile instrument ready when it must be, a handoff done cleanly, a team that does not let a rushed schedule turn into a bad outcome. That is why Lara L. Kirchner's recognition as a Pinnacle Professional of the Year deserves a more serious look than the usual congratulatory confetti. Kirchner is...

Continue Reading
CVRx Lawsuit Puts Barostim Sales Claims Under Hard Scrutiny

Updated Category News Views 121

August 7 turned a compliance disclosure into a wrecking ball for CVRx shareholders. After the company revealed a Department of Justice civil investigative demand and cut its outlook, the stock dropped $3.55, or 60%, to close at $2.39. That is not a routine bad quarter getting punished. It is the market abruptly questioning whether the sales engine, the revenue it...

Continue Reading
California Stone Ban Puts a Hidden Worker Toll in View

Updated Category News Views 42

Countertops are supposed to finish a kitchen, not quietly wreck the lungs of the people cutting them. Yet California's move toward prohibiting the fabrication and installation of artificial stone containing more than 1% crystalline silica puts an ugly, long-running occupational-health problem in plain sight. This is not a story that calls for chest-thumping market talk....

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 73

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
ASU's International Enrollment Lead Carries Real Weight

Updated Category News Views 108

Twenty thousand nine hundred twenty-six international students is not a campus footnote; it is a serious operating force moving through Arizona State University and the state around it. ASU has held the No. 1 spot among U.S. public universities hosting international students for six straight years, and the 2026 Open Doors report puts it No. 2 across public and private...

Continue Reading
Fervo IPO Lawsuit Puts 71% Share Collapse in Focus

Updated Category News Views 61

Fervo’s $27 debut has turned into the sort of wreckage IPO buyers dread: shares were alleged to have closed as low as $7.79 when the complaint was filed. That is more than a 71% fall from the May 13, 2026 offering price, and it puts a hard, ugly number beside the new securities class action against the geothermal power developer. More Than a Bad Quarter Is Being Alleged...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 90

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading
Jalisco’s Culinary Push Puts Tourism Strategy in Focus

Updated Category News Views 50

A destination sells itself twice: first with a memorable meal, then with a reason to come back. Jalisco’s stated effort to connect the world’s cuisines through The 50 Best Gastronomic Experiences belongs in that second category. It is not merely restaurant chatter. It reads as part of a broader attempt to make the state’s tourism offering feel deeper, more varied...

Continue Reading

Top 5 Most Recently Viewed Articles

Nukkleus Stock Skyrockets 16% After Major Decision

Updated Category News Views 330

Nukkleus Inc. Stock Soars in After-Hours Trading Nukkleus Inc. (NASDAQ: NUKK) is making headlines as its shares have surged during after-hours trading following important developments within the company. This noteworthy stock movement reflects both investor sentiment and strategic changes that the company is undergoing. After-Hours Rally Sparks Investor Interest In recent...

Continue Reading
Tambourine One Revolutionizes Hotel Booking Experiences

Updated Category News Views 135

Introducing Tambourine One: A New Era in Hotel Booking Tambourine, the renowned leader in hotel marketing technology, has launched an innovative product known as Tambourine One. This all-in-one solution merges their advanced website technology with a booking engine, aimed at boosting direct bookings for hotels and resorts. By enhancing the booking process, Tambourine One...

Continue Reading
Midwest Great Dane: A New Era for Trudell Trailer Sales

Updated Category News Views 217

Midwest Great Dane Reveals Brand Transformation Midwest Great Dane, previously known as Trudell Trailer Sales, is making waves in the transportation and trucking industry with its recent name change. This transformation stems from a strategic acquisition by Cox Automotive, aimed at enhancing their representation of the Great Dane brand in the Midwest. The organization's...

Continue Reading
SoftServe Launches New Partner Unit to Boost AI Solutions

Updated Category News Views 334

SoftServe Unveils New Partner Business Unit for Enhanced AI Services SoftServe has officially launched its first dedicated Partner Business Unit (BU), marking a significant step forward in its strategic partnership with Microsoft. This initiative is designed to leverage SoftServe's extensive experience in technology and digital services, ensuring that organizations can...

Continue Reading
Portugal's Agri-Food Push in Canada: A Taste for Growth

Updated Category News Views 52

Eyeing Fresh Opportunities in Canada Here's a hot one for you—Portugal's agri-food sector is making a notable splash over in Canada. Yeah, you heard it right. Amidst the hustle and bustle of the SIAL Canada, which isn't just any minor shindig, "Taste & Feel Portugal 2.0" aims to put Portugal's top-tier grub on the map. It's about more than nibbling on cheese; it's a...

Continue Reading